EUVIMEDEUVIMED entdecken
Crossref

Discovery of orally bioavailable N-acylated remdesivir derivatives with potent broad-spectrum antiviral activity

Letian Song, Bing Ye, Baohu Li, Leentje Persoons, Dirk Jochmans, Johan Neyts, Steven De Jonghe, Shenghua Gao, Peng Zhan, Xinyong Liu

Bioorganic Chemistry · 2026-07 · 175 · 109758

DOI: 10.1016/j.bioorg.2026.109758 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-07. Verfasst von Letian Song und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead Compounds, State Key Laboratory of Di…. Hauptthemen laut MEDLINE: Antiviral Agents, Alanine, Adenosine Monophosphate, Drug Discovery. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Hercules Foundation, Ministry of Science and Technology of the People's Republic of China, Department of Science and Technology of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Remdesivir (RDV), a nucleoside analog targeting viral RNA-dependent RNA polymerase (RdRp), suffers from critical limitations including low oral bioavailability, plasma instability, and reliance on intravenous administration, hindering its clinical utility. To address these issues, we designed and synthesized 28 novel N-acylated derivatives by modifying the amino group on remdesivir's triazine ring. The lead compound 4f exhibited potent anti-SARS-CoV-2 activity (EC50 = 0.0862 μM) in Vero E6 cells, comparable to remdesivir (EC50 = 0.0459 μM), with reduced cytotoxicity (CC50 = 15.6 μM, SI = 181.0). Notably, 4f displayed broad-spectrum efficacy against human coronaviruses (HCoV-229E and HCoV-OC43), zika virus (ZIKV), and yellow fever virus (YFV), matching remdesivir's potency. Pharmacologically, 4f showed significantly enhanced plasma stability (half-life >8 h vs. 2 h for RDV) and reduced CYP3A4 inhibition (23.8% vs. 57.4% for RDV at 10 μM). In vivo pharmacokinetics confirmed its superior oral bioavailability (45.3% based on active metabolite GS-441524 exposure), efficiently delivering GS-441524 into systemic circulation. This N-acylation strategy overcomes key pharmacokinetic barriers of remdesivir while preserving broad-spectrum antiviral activity, highlighting 4f as a promising oral candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsAlanineAdenosine MonophosphateDrug DiscoveryAnimalsAdministration, OralHumansBiological AvailabilityChlorocebus aethiopsVero CellsSARS-CoV-2Structure-Activity RelationshipAcylationCOVID-19 Drug TreatmentMolecular StructureMicrobial Sensitivity TestsDose-Response Relationship, Drug

Stichwörter der Autor:innen

Broad-spectrumNucleosideProdrugRdRp inhibitorSARS-CoV-2

Substanzen

Antiviral AgentsremdesivirAlanineAdenosine Monophosphate

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead Compounds, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chines…
  • KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Molecular Genetics and Therapeutics in Virology and Oncology Research Group, Herestraat 49, box 1048, 3000 Leuv…
  • KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Antiviral Drug & Vaccine Research Group, Herestraat 49, box 1043, B-3000 Leuven, Belgium.
  • KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Molecular, Structural and Translational Virology Research Group, Herestraat 49, box 1049, B-3000 Leuven, Belgiu…

Förderung

  • Hercules Foundation
  • Ministry of Science and Technology of the People's Republic of China
  • Department of Science and Technology of Shandong Province
  • National Natural Science Foundation of China
  • Shandong Province Department of Education
  • Fonds Wetenschappelijk Onderzoek
  • KU Leuven Rega Foundation
  • National Key Research and Development Program of China

Zitieren

APA

Song, L., Ye, B., Li, B., Persoons, L., Jochmans, D., Neyts, J., De Jonghe, S., Gao, S., Zhan, P., & Liu, X. (2026). Discovery of orally bioavailable N-acylated remdesivir derivatives with potent broad-spectrum antiviral activity. Bioorganic Chemistry, 175, 109758. https://doi.org/10.1016/j.bioorg.2026.109758

Vancouver

Song L, Ye B, Li B, Persoons L, Jochmans D, Neyts J, et al. Discovery of orally bioavailable N-acylated remdesivir derivatives with potent broad-spectrum antiviral activity. Bioorganic Chemistry. 2026;175:109758. doi:10.1016/j.bioorg.2026.109758

BibTeX
@article{Song2026,
  author = {Song, Letian and Ye, Bing and Li, Baohu and Persoons, Leentje and Jochmans, Dirk and Neyts, Johan and De Jonghe, Steven and Gao, Shenghua and Zhan, Peng and Liu, Xinyong},
  title = {Discovery of orally bioavailable N-acylated remdesivir derivatives with potent broad-spectrum antiviral activity},
  journal = {Bioorganic Chemistry},
  year = {2026},
  volume = {175},
  pages = {109758},
  doi = {10.1016/j.bioorg.2026.109758}
}
Kostenlos starten →